#Multispecific
Ichnos Glenmark Innovation Advances Cancer Therapy with ISB 2301 IND Submission to FDA#USA#New_York#FDA#Ichnos_Glenmark#ISB_2301
Ichnos Glenmark Innovation Advances Cancer Therapy with ISB 2301 IND Submission to FDA
Ichnos Glenmark Innovation, Inc. has announced the filing of an IND with the FDA for ISB 2301, a pioneering multispecific immune cell activator targeting solid tumors, expected to enter clinical trials.
third-news.com
November 18, 2026 at 8:10 AM
Ichnos Glenmark Innovation Submits IND Application for ISB 2301, A Breakthrough Treatment for Solid Tumors#USA#New_York#Ichnos_Glenmark#ISB_2301#Multispecific
Ichnos Glenmark Innovation Submits IND Application for ISB 2301, A Breakthrough Treatment for Solid Tumors
Ichnos Glenmark Innovation (IGI) has announced the submission of an IND application for ISB 2301, highlighting its potential in treating solid tumors. This milestone is pivotal for IGI's innovative oncology pipeline.
third-news.com
November 18, 2026 at 8:09 AM
🚨 $APVO
On November 9, 2026, Aptevo Therapeutics Inc. issued a press release announcing that on November 7, 2026, the Company presented new preclinical data from its next-generation multispecific platform at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting.
SEC Filing: APVO
Click to view the official SEC document.
www.sec.gov
November 9, 2026 at 1:35 PM
US20260327283A1: Avidicure's IL-21/4-1BBL multispecific proteins combine NK-cell expansion and activation via Fc/CD16A and optional NKp46. AVC-009/011/014 achieved feeder-cell-comparable ex-vivo expansion and MDA-MB-231 cytotoxicity.
October 31, 2026 at 2:56 PM
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Review Highlight -Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy.
doi.org/10.1093/abt/...
#bispecific #bispecificantibody #bispecificantibodies #bsab #bsabs #tcellengagers #cd3 #mab
October 30, 2026 at 2:05 PM
Researchers are developing novel molecule classes, including ADCs and multispecific antibodies, which promise better selectivity and lower tissue damage compared to existing treatments.

#AntibodyDrugConjugates #Oncology #ProteinTherapeutics
New protein molecules reduce toxicity
Source: BioPharma Dive
realfeedapp.com
October 26, 2026 at 11:20 AM
Interest is growing in multispecific antibodies to target tumour types that are unresponsive to current #immunotherapy, as illustrated by #ClinicalTrials presented at #ESMO26 in #ColorectalCancer and #ClearCellRenalCellCarcinoma
🔗 https://ow.ly/NL5a50ZZspP

#InsightsbyESMO

@mdcurioni.bsky.social
October 25, 2026 at 7:30 AM
Zealand Pharma and Generate Biomedicines will design multispecific proteins for metabolic disease, in a deal with nearly $1.2b in milestones.

Link as first comment.

#longevity #ZealandPharma #GenerateBiomedicines #metabolicdisease #biotech
October 23, 2026 at 10:18 AM
Generate Biomedicines lands $30m upfront plus $1.2bn in milestones from Zealand Pharma to design AI-engineered multispecific proteins for obesity and metabolic disease.
Generate Biomedicines and Zealand Pharma ink AI protein deal
Generate Biomedicines will receive $30m upfront and up to $1.2bn in milestones to design AI-engineered multispecific proteins for obesity and metabolic disease.
thebiotechtimes.com
October 21, 2026 at 1:35 PM
Zealand Pharma and Generate Biomedicines are partnering on AI-designed multispecific proteins for obesity and metabolic disease. $30m upfront, with $1.2bn in milestones.
Zealand Pharma and Generate Biomedicines partner on AI protein drugs
Zealand Pharma will pay Generate Biomedicines $30m upfront, with milestones of nearly $1.2bn, to design AI-engineered multispecific proteins for obesity and metabolic
thebiotechtimes.com
October 21, 2026 at 1:10 PM
$APVO — Other Company Update

Aptevo Therapeutics Inc. (Nasdaq: APVO) filed an 8-K announcing via press release that its multispecific platform will be presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, held November 4–8, 2026, in Phoenix, Arizona.

🧵 continued ↓
October 14, 2026 at 3:15 PM
🚨 $APVO
On October 14, 2026, Aptevo Therapeutics Inc. issued a press release announcing its multispecific platform will be presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, being held November 4–8, 2026, at the Phoenix Convention Center in Phoenix, Arizona.
SEC Filing: APVO
Click to view the official SEC document.
www.sec.gov
October 14, 2026 at 12:52 PM
(JASMS) BioDRUMs: An Open-Source Python Pipeline for Automated
Mean Drug-to-Antibody Ratio and Biologics Structural Integrity Analysis
from High-Resolution Mass Spectrometry Data: AbstractDrug-to-antibody
ratio and structural integrity represent two critical
quality attributes… (RSS) #MassSpecRSS
BioDRUMs: An Open-Source Python Pipeline for Automated Mean Drug-to-Antibody Ratio and Biologics Structural Integrity Analysis from High-Resolution Mass Spectrometry Data
AbstractDrug-to-antibody ratio and structural integrity represent two critical quality attributes for antibody-drug conjugates and multispecific biologics in development. Intact mass spectrometry analysis of biologics is crucial to understanding the behavior of a new candidate, especially for complex modalities. Sample preparation is relatively robust and easy to reproduce in different laboratories and by different operators. However, mass spectrometric analysis and data processing represent the two most limiting steps. So far, no automated open-source pipeline has been published, which can automatically postprocess deconvoluted spectrum outputs from different vendors, plot data, and provide an overall interpretation of mean DAR and deep ADC characterization, especially on in vivo samples. BioDRUMs offers different features that complement existing commercial mass spectrometry deconvolution tools, such as customizable degradation-hypothesis generation, isobaric-species ambiguity reporting, vendor-neutral postprocessing of deconvoluted mass tables, structural-integrity scoring, automated plotting, and reporting. Streamlining data analysis of the mean drug-to-antibody ratio and structural integrity can accelerate and provide uniform data outputs and result delivery across different in vitro/in vivo studies. Moreover, a user-friendly pipeline would enable scientists to perform such an analysis for the first time more confidently, without requiring any pre-existing coding skills. In this work, we present BioDRUMs (Biologics Drug Ratio and Unified intact Mass analysis), an automated Python pipeline to simplify data analysis of the mean drug-to-antibody ratio and structural integrity analysis of biologics and bioconjugates. A graphical user interface (GUI) and a Web app interface have also been implemented to make it user-friendly for users with little to no prior programming knowledge.
dlvr.it
October 7, 2026 at 1:02 AM
Envisagenics and Boehringer Ingelheim have signed a $1bn deal. The biotech's AI platform will identify tumour-specific targets for Boehringer's ADC, T-cell engager and multispecific antibody programmes.
Envisagenics and Boehringer Ingelheim in $1bn RNA splicing deal
Envisagenics' AI-powered SpliceCore platform will supply tumour-specific targets to Boehringer across ADC, T-cell engager and multispecific antibody programmes.
biotech.disruptsmedia.com
September 27, 2026 at 6:27 PM
Boehringer Ingelheim Taps Envisagenics for RNA Splicing Tech in $1B Deal
Boehringer Ingelheim Taps Envisagenics for RNA Splicing Tech in $1B Deal
The companies will identify targets for antibody-drug conjugates, T cell engagers, and multispecific antibodies.
ebx.sh
September 23, 2026 at 6:50 PM
Peptide-Drug Conjugates (#PDCs) combine targeted peptides with potent drug payloads.
🎯TwoStep Therapeutics’TS-104 is a multispecific PDC targeting five tumor-associated integrins: αvβ3, αvβ5, αvβ6, αvβ1, and α5β1, with MMAE as its cytotoxic payload. FDA-cleared IND, with Phase 1 expected this year.
September 11, 2026 at 12:01 PM
Nature research paper: Proximity-guided graph learning reveals tumour-associated proximity antigens

go.nature.com/4gYIZ60
Proximity-guided graph learning reveals tumour-associated proximity antigens - Nature
A proximity-mapping atlas defines tumour-associated proximity antigens, revealing disease-associated membrane spatial communities, and identifies EGFR–CDCP1 as a co-target pair that enhances tumour killing by multispecific therapeutics.
go.nature.com
September 10, 2026 at 2:52 PM
Nearly a decade ago, Niyi and I began exploring photocatalysis to map protein spatial organization. Our new @nature.com
paper shows how protein proximity can reveal therapeutic target pairs and guide multispecific medicines.

www.nature.com/articles/s41...
Proximity-guided graph learning reveals tumour-associated proximity antigens - Nature
A proximity-mapping atlas defines tumour-associated proximity antigens, revealing disease-associated membrane spatial communities, and identifies EGFR–CDCP1 as a co-target pair that enhances&nbsp...
www.nature.com
September 10, 2026 at 8:54 PM
WO2026179945A1 discloses a HER3×TROP2 multispecific ADC for NSCLC, tested in xenografts and an osimertinib-resistant PDX. Claims include PD-1 blockade ± platinum, with Q3W ADC dosing of 3–8 mg/kg.
September 10, 2026 at 5:36 AM
Last week’s filings span ADCs, multispecific proteins, CNS delivery and in-vivo cell engineering: EGFR×B7-H3 ADCs, FGFR3 S249C×CD3 engagers, orthogonal IL-21 signalling, brain-targeted progranulin/AAVs and CRISPR CAR-T generation, with preclinical data highlighting key translational caveats.
September 8, 2026 at 8:19 AM
US20260248911A1 discloses multispecific pMHC-based molecules that selectively target antigen-specific TCR clonotypes, with CD28 co-stimulation or CD20 binding. GP33/OVA systems showed clonotype-selective proliferation and antigen-specific lytic activity in vitro and in vivo.
September 4, 2026 at 6:53 AM